Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats non-esophageal mucus membrane gastrointestinal candidiasis. ANDA 62506, held by Teva. Nystatin.
As of Nov 14, 2026, ANDA 62506 (Nystatin), held by Teva, was first approved by FDA on Jan 16, 1984, with 32 approved supplements and 0 published complete response letters.
First approved: Jan 16, 1984
Supplements approved: 32
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
INDICATIONS AND USAGE Nystatin tablets are intended for the treatment of non-esophageal mucus membrane gastrointestinal candidiasis.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
